传教士
China approves first-ever drug for acute mountain sickness prevention_我的网站
A | 据1月13日《科学技术日报》官方微博报道，1月12日，湖北省武汉市中科院水产研究所展出了一只白鳍豚的3D打印标本。
China has granted marketing approval of its first drug for the prevention of acute mountain sickness, filling the long-standing gap in the domestic market where no such medications had been available, Science and Technology Daily reported on Tuesday.
The National Medical Products Administration (NMPA) has approved the marketing of acetazolamide sustained-release capsules, the report said. As the first specialized drug in China indicated for preventing of acute mountain sickness, its approval marks the end of the country's lack of dedicated preventive treatment for altitude illness.
By inhibiting the activity of carbonic anhydrase, acetazolamide promotes the renal excretion of bicarbonate, corrects respiratory alkalosis caused by hypoxia at high altitudes, thereby regulating acid-base balance, optimizing respiratory status, elevating blood oxygen levels, and reducing the risk of onset at the source.
In contrast to health products that only provide auxiliary regulatory effects, this medication has been validated through stringent clinical trials and stands as a specialized drug approved by the NMPA with a clear indication for prevention, said the report.
Led by principal investigator is Luobu Gesang, a deputy dean of the People's Hospital of Xizang Autonomous Region, the clinical trial was designed by his team and has yielded critical evidence to inform prevention strategies for altitude sickness that are specifically adapted to Chinese and Asian populations.
"Previously, although acetazolamide had already been used internationally for the prevention of acute mountain sickness, China had long lacked an NMPA-approved acetazolamide formulation supported by rigorous clinical trials. Furthermore, the existing international formulations were short-acting tablets requiring multiple daily doses, and no drugs with the relevant indication were available on the domestic market for an extended period," said Luobu Gesang.
The sustained-release capsule approved this time not only fills this critical gap but also optimizes the dosage form, providing more reliable and convenient medication protection for the physical health and life safety of people entering high-altitude areas, he added.
Clinical trials showed that, compared with the placebo group, the incidence of acute mountain sickness in the medication group was significantly reduced, with the incidence of moderate-to-severe acute mountain sickness decreasing by 14.6 percent, according to the report.
Related research has been published in the international flagship journal of high-altitude medicine, High Altitude Medicine & Biology.
Global Times
。这是我国第一个三维印制生物标本。据报道，“齐琪”被认为是最后一只白海豚，在2002年被囚禁22年后死亡。3-D打印样本长2.07米，重约7公斤。它是从三维打印构建的“冰淇淋”三维数据模型中恢复出来的。
B | 据报道，“奇奇”是世界上最长的圈养海豚。1980年被渔民捕获并送往水生栖息地。自从2002年它死后，没有人见过活海豚。白鳍豚（学名：白鳍豚，lipotes vexillifer），又名：白鲸、白鳍、白旗、白夹、绿鳍、琵琶、中国鼠海豚、长江鼠海豚、长江河豚，是我国特有的淡水鲸种，只产于长江中下游。20世纪80年代，由于各种原因，海豚的数量急剧下降。2002年，据估计有不到50只海豚，被称为“水中大熊猫”。海豚属于自己的家族，被列为国家一级保护野生动物和世界上12种最濒危动物之一。2007年8月8日，一份报告发表在《英国皇家学会生物学快报》上，正式宣布了海豚的功能性灭绝。
Current article:http://www.ninyakenhongnian.sbs/list_ta0j/9rwu8j4.xls
Published on:19:59:45
